Table 1 Demographic and clinical characteristics in the drug-treated and untreated IgAN patients at the time of kidney biopsy and at the end of follow-up

N

73

65

38

27

Age (years)

33.7 (16–76)

33.9 (16–76)

37.5 (16–76)

28.8 (16–46)*

Duration of follow-up (months, range)

48.9 (12–144)

46.4 (12–144)

52.8 (12–135)

BMI (kg/m²)

26.4 ± 5.2

27.1 ± 4.8

27.5 ± 5.4

25.2 ± 4.7*

Smokers (%)

29

27.7

31.6

22.2

 Macroscopic hematuria (%)

4

4.6

0

11.1

 Asymptomatic microhematuria (%)

48

44.6

34.2

59.3

 Asymptomatic microhematuria and proteinuria (%)

39

41.5

50.0

29.6

 NS (%)

7

6.2

10.5

0

 Acute renal failure (%)

1

1.5

2.6

0

 CKD (eGFR < 60 ml/min/1.73 m²) (%)

1

1.5

2.6

0

MAP (mmHg)

94.5 ± 16.7

95.2 ± 9.1

96.2 ± 9.9

93.9 ± 7.7

S-Creat (μmol/L)

93.4 ± 70.7

94.4 ± 74.4

106.1 ± 94.4

77.2 ± 15.0*

eGFR (mean, ml/min per 1.73 m²)

94.9 ± 30.7

85.8 ± 28.6

76.5 ± 29.1

98.8 ± 22.5**

eGFR >90 ml/min (N)

38

34

16

18

eGFR 60–89 ml/min (N)

21

18

11

7

eGFR >60 ml/min (N)

13

13

11

2

U-Prot (g/day, range)

0.91 (0–10.2)

0.79 (0–8.5)

1.0 (0–8.5)

0.5 (0–3.5)*

<1 (%)

81

79

73.7

85.2

1–3.49 (%)

11

15

13.2

14.8

>3.5 (%)

8

6

10.5

0

Microhematuria (%)

65.8

40.0

39.5

40.7